Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Trial Profile

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LOXO-338 (Primary) ; Pirtobrutinib (Primary)
  • Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 15 Jun 2023 Results (As of 18 October 2022,n= 22 ), presented at the 28th Congress of the European Haematology Association
    • 30 May 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2023.
    • 30 May 2023 Planned primary completion date changed from 1 Apr 2024 to 1 May 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top